Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics

Biopharmaceutical company focused on exploring effects of cytokine based therapies on cancer.

Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company that is focused on exploring the role that cytokine-based therapies can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer treatments.

The company's leading product candidate is IRX-2, a cytokine based therapy. It delivers IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, thereby enabling the immune system to attack cancer cells. In a Phase 2A clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which is associated with a survival benefit in patients with head and neck cancer. Brooklyn ImmunoTherapeutics has initiated a Phase 2B clinical study of IRX-2 in patients with squamous cell cancer of the head and neck, with results expected to be reported in 2020.

The company is also exploring the potential of IRX-2 in other oncology indications in collaboration with multiple pharmaceutical companies. Clinical trials in combination with other anti-cancer agents such as checkpoint inhibitors are also being conducted.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Lynn Sadowski Mason

VP, Clinical Operations

Mark Leuchtenberger

Interim CEO

Michael Wyand

Senior Technical Advisor

Monil Shah

COO

Ron Guido

Senior VP, Regulatory Affairs and Quality Systems

Further reading

Title
Author
Link
Type
Date

Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

Business Wire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.